Patents by Inventor Jonathan LEHRER

Jonathan LEHRER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF IMMUNE CELL-SPECIFIC GENE EXPRESSION FOR PROGNOSIS OF PROSTATE CANCER AND PREDICTION OF RESPONSIVENESS TO RADIATION THERAPY
    Publication number: 20260185166
    Abstract: Methods, systems, and kits for the diagnosis, prognosis and the determination of cancer progression of prostate cancer in a subject are disclosed. In particular, the disclosure relates to the use of immune cell-specific gene expression in determining prognosis and identifying individuals in need of treatment for prostate cancer who will be responsive to radiation therapy.
    Type: Application
    Filed: December 15, 2025
    Publication date: July 2, 2026
    Inventors: Elai Davicioni, Nicholas George Erho, Jonathan Lehrer, Felix Y. Feng, Shuang G. Zhao
  • Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
    Patent number: 12497660
    Abstract: Methods, systems, and kits for the diagnosis, prognosis and the determination of cancer progression of prostate cancer in a subject are disclosed. In particular, the disclosure relates to the use of immune cell-specific gene expression in determining prognosis and identifying individuals in need of treatment for prostate cancer who will be responsive to radiation therapy.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: December 16, 2025
    Assignee: Veracyte SD, Inc.
    Inventors: Elai Davicioni, Nicholas George Erho, Jonathan Lehrer, Felix Y. Feng, Shuang G. Zhao
  • USE OF IMMUNE CELL-SPECIFIC GENE EXPRESSION FOR PROGNOSIS OF PROSTATE CANCER AND PREDICTION OF RESPONSIVENESS TO RADIATION THERAPY
    Publication number: 20210317531
    Abstract: Methods, systems, and kits for the diagnosis, prognosis and the determination of cancer progression of prostate cancer in a subject are disclosed. In particular, the disclosure relates to the use of immune cell-specific gene expression in determining prognosis and identifying individuals in need of treatment for prostate cancer who will be responsive to radiation therapy.
    Type: Application
    Filed: August 2, 2018
    Publication date: October 14, 2021
    Inventors: Elai DAVICIONI, Nicholas George ERHO, Jonathan LEHRER, Felix Y. FENG, Shuang G. ZHAO